SynthesisScientific reports2026
Adjunctive linaclotide improves bowel cleansing and patient experience in polyethylene glycol-based bowel preparation.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Adequate bowel preparation is critical for successful colonoscopy but is often compromised by the large volume and poor palatability of polyethylene glycol (PEG) solutions, leading to poor patient adherence. Linaclotide, a secretagogue, may enhance the efficacy and tolerability of PEG-based regimens. We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library for randomized controlled trials (RCTs) evaluating the addition of linaclotide to various PEG-based bowel preparation regimens (including different PEG volumes and formulations such as PEG with ascorbic acid). Primary outcomes were the rate of adequate bowel preparation and bowel preparation scores (Boston Bowel Preparation Scale [BBPS] and Ottawa Bowel Preparation Scale [OBPS]). Secondary outcomes included polyp detection rate (PDR), adenoma detection rate (ADR), and patient tolerance. Data were pooled using a random-effects model, and results were expressed as odds ratios (OR) or mean differences (MD) with 95% confidence intervals (CI). Nine RCTs with 2228 participants were included. The pooled analysis showed that regimens containing linaclotide as an adjunct to PEG-based solutions significantly increased the rate of adequate bowel preparation compared to control regimens (91.2% vs. 84.3%; OR: 1.89, 95% CI: 1.34-2.66, p < 0.01) and yielded better BBPS (MD: 1.15, 95% CI: 0.28-2.01, p < 0.01) and OBPS scores (MD: - 0.75, 95% CI: - 1.19 to - 0.31, p < 0.01). Notably, low-volume PEG plus linaclotide showed no statistically significant difference in the rate of adequate bowel preparation compared to high-volume PEG alone. The linaclotide combination groups also demonstrated significantly improved patient tolerability, with a lower incidence of adverse symptoms (abdominal pain, bloating, nausea, vomiting) and a higher willingness to repeat the preparation. There were no significant differences in PDR or ADR between groups. The adjunctive use of linaclotide significantly improves the quality of bowel preparation and enhances patient tolerance for PEG-based regimens. It enables effective cleansing with a low-volume PEG solution, offering a promising strategy to improve patient compliance and experience without compromising preparation quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.